Regenerative principles enrich cardiac rehabilitation practice
- PMID: 25313663
- PMCID: PMC4197403
- DOI: 10.1097/PHM.0000000000000147
Regenerative principles enrich cardiac rehabilitation practice
Abstract
Cardiovascular morbidity imposes a high degree of disability and mortality, with limited therapeutic options available in end-stage disease. Integral to standard of care, cardiac rehabilitation aims on improving quality-of-life and prolonging survival. The recent advent of regenerative technologies paves the way for a transformative era in rehabilitation medicine whereby, beyond controlling risk factors and disease progression, the prospect of curative solutions is increasingly tangible. To date, the spectrum of clinical experience in cardiac regenerative medicine relies on stem cell-based therapies delivered to the diseased myocardium either acutely/subacutely, after a coronary event, or in the setting of chronic heart failure. Application of autologous/allogeneic stem cell platforms has established safety and feasibility, with encouraging signals of efficacy. Newer protocols aim to purify cell populations in an attempt to eliminate nonregenerative and enrich for regenerative cell types before use. Most advanced technologies have been developed to isolate resident cell populations directly from the heart or, alternatively, condition cells from noncardiac sources to attain a disease-targeted lineage-specified phenotype for optimized outcome. Because a multiplicity of cell-based technologies has undergone phase I/II evaluation, pivotal trials are currently underway in larger patient populations. Translation of regenerative principles into clinical practice will increasingly involve rehabilitation providers across the continuum of patient care. Regenerative rehabilitation is thus an emerging multidisciplinary field, full of opportunities and ready to be explored.
Figures

Similar articles
-
Disease-in-a-dish: the contribution of patient-specific induced pluripotent stem cell technology to regenerative rehabilitation.Am J Phys Med Rehabil. 2014 Nov;93(11 Suppl 3):S155-68. doi: 10.1097/PHM.0000000000000141. Am J Phys Med Rehabil. 2014. PMID: 25122102 Free PMC article. Review.
-
Regenerative rehabilitation: a new future?Am J Phys Med Rehabil. 2014 Nov;93(11 Suppl 3):S73-8. doi: 10.1097/PHM.0000000000000211. Am J Phys Med Rehabil. 2014. PMID: 25310603 Free PMC article.
-
Clinical Studies of Cell Therapy in Cardiovascular Medicine: Recent Developments and Future Directions.Circ Res. 2018 Jul 6;123(2):266-287. doi: 10.1161/CIRCRESAHA.118.311217. Circ Res. 2018. PMID: 29976692 Free PMC article. Review.
-
Gene therapy for inherited muscle diseases: where genetics meets rehabilitation medicine.Am J Phys Med Rehabil. 2014 Nov;93(11 Suppl 3):S97-107. doi: 10.1097/PHM.0000000000000138. Am J Phys Med Rehabil. 2014. PMID: 25313664 Free PMC article. Review.
-
Regenerative medicine techniques in cardiovascular disease: where is the horizon?Regen Med. 2013 May;8(3):351-60. doi: 10.2217/rme.13.21. Regen Med. 2013. PMID: 23627828
Cited by
-
Mechanisms and Therapeutic Targets of Cardiac Regeneration: Closing the Age Gap.Front Cardiovasc Med. 2018 Feb 5;5:7. doi: 10.3389/fcvm.2018.00007. eCollection 2018. Front Cardiovasc Med. 2018. PMID: 29459901 Free PMC article. Review.
-
Regional Variability in the Access to Cardiac Rehabilitation in Poland.Healthcare (Basel). 2020 Nov 9;8(4):468. doi: 10.3390/healthcare8040468. Healthcare (Basel). 2020. PMID: 33182292 Free PMC article.
-
Prion Protein and Stage Specific Embryo Antigen 1 as Selection Markers to Enrich the Fraction of Murine Embryonic Stem Cell-Derived Cardiomyocytes.Yonago Acta Med. 2016 Jun 29;59(2):126-34. eCollection 2016 Jun. Yonago Acta Med. 2016. PMID: 27493483 Free PMC article.
References
-
- Terzic A, Harper CM, Jr, Gores GJ, Pfenning MA. Regenerative medicine blueprint. Stem cells and development. 2013;22(Suppl 1):20–24. - PubMed
-
- Waldman SA, Terzic A. Cardiovascular health: the global challenge. Clinical pharmacology and therapeutics. 2011;90:483–485. - PubMed
-
- Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. The New England journal of medicine. 1991;325:293–302. - PubMed
-
- Domanski MJ, Krause-Steinrauf H, Massie BM, et al. A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail. 2003;9:354–363. - PubMed
-
- Gheorghiade M, Pitt B. Digitalis Investigation Group (DIG) trial: a stimulus for further research. American heart journal. 1997;134:3–12. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical